After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback